NCT01012817 2025-09-15Veliparib and Topotecan Hydrochloride in Treating Patients With Solid Tumors, Relapsed or Refractory Ovarian Cancer, or Primary Peritoneal CancerNational Cancer Institute (NCI)Phase 1/2 Active not recruiting88 enrolled 23 charts
NCT02419495 2025-06-04Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced MalignanciesM.D. Anderson Cancer CenterPhase 1 Terminated221 enrolled